Company: Dr. Reddy's Laboratories Ltd. Category: Company News


The detailed safety and efficacy data from the study would be presented in future dermatology conferences
June 10, 2019, 2:15 p.m.

The company has received the Establishment Inspection Report (EIR) from USFDA, for the facility, indicating closure of the audit and the inspection classification of this facility is determined as Voluntary Action Initiated.
May 31, 2019, 9:26 a.m.

The company reported revenue growth of 13.4% yoy to Rs4,029.6cr, broadly in-line with consensus estimates.
May 20, 2019, 3:16 p.m.

The revenues from India during the Q4 was at ₹650 crore.For FY19, PAT stood at ₹1,880 crore while revenue was 15,385 crore
May 17, 2019, 7:40 p.m.
Publisher: livemint.com


Divestment of derma assets, lower operating costs helped firm post higher profit growth during the quarter
May 17, 2019, 7:26 p.m.

Dr Reddy’s Laboratories Ltd reported that its consolidated net profit increased by 44 per cent at Rs 434 crore in the fourth quarter ended March 31,
May 17, 2019, 4:15 p.m.

Revenue for the quarter under discussion was up by 14 per cent at Rs 4,016.60 crore against Rs 3,534.90 crore in the same quarter last fiscal
May 17, 2019, 3:42 p.m.

Revenue for the quarter under discussion was up by 14 per cent at Rs 4,016.60 crore against Rs 3,534.90 crore in the same quarter last fiscal
May 17, 2019, 3:42 p.m.

The Cubicin for Injection (daptomycin for injection) brand and generic had US sales of ~$640.8mn MAT for the most recent twelve months ending in March 2019, according to IQVIA Health.
May 15, 2019, 12:40 p.m.

As per IQVIA Health data, the AndroGel (testosterone gel) brand and generic had US sales of ~$815.6mn MAT for the most recent twelve months ending in February 2019.
May 6, 2019, 2:52 p.m.

-->